Investigational device labeling should communicate investigational status, relevant risks, and the information needed for controlled use in the study. For U.S. investigations subject to the applicable IDE labeling provisions, 21 CFR 812.5 sets specific requirements. Label design also needs to remain consistent with the protocol, device configuration, and investigational plan.
FDA requirements for investigational device labeling
The device or immediate package must identify the manufacturer, packer, or distributor and place of business, state the quantity when appropriate, and carry the prescribed investigational-use caution. Relevant contraindications, hazards, adverse effects, interfering substances or devices, warnings, and precautions must appear in the label or other labeling.
CAUTION—Investigational device. Limited by Federal (or United States) law to investigational use.
Labeling must not be false or misleading or represent the device as safe or effective for the use under investigation.
Separate required content from study-specific controls
| Labeling element | How to assess it |
|---|---|
| Investigational-use statement | Apply the prescribed caution for the applicable investigation. |
| Business identification and quantity | Check the requirements in 21 CFR 812.5 and the referenced identification rules. |
| Risk information | Assess relevant hazards, warnings, precautions, and other required information. |
| Model, version, lot, or serial number | Define traceability appropriate to the device and study. |
| Protocol, site, or study reference | Include where useful for controlled distribution and accountability. |
| Storage, expiry, handling, and disposal | Assess product-specific needs and consistency with the investigational plan. |
Not every practical field in a study label is independently mandated by 21 CFR 812.5. Identify the basis for each element so the team can distinguish regulatory requirements from sponsor controls and product-specific decisions.
Review the label against the IDE and clinical protocol
Use a controlled checklist to compare the label, instructions for use, protocol, investigator materials, and device specifications. Check the product name, configuration, intended investigational use, storage instructions, warnings, and any use limitations across the documents.
FDA’s IDE information also identifies a different caution for devices used solely in laboratory animals or other nonhuman tests. Do not reuse the human-investigation label without checking the relevant context.
Best practices for labeling control
- Define ownership. Assign regulatory, quality, clinical, and technical review responsibilities.
- Use a controlled master. Identify the approved version, artwork, languages, and device configurations covered.
- Check practical readability. Confirm that text remains legible at the actual label size and under expected handling conditions.
- Control changes. Assess the effect of a device, protocol, packaging, or risk-information change before issuing revised labeling.
- Reconcile distribution. Maintain the relationship between label versions, device identifiers, shipments, and study sites.
- Train relevant personnel. Explain investigational status, handling instructions, and the escalation process for a mismatch.
Common investigational labeling mistakes
Avoid promotional claims, an investigational statement presented as optional sample wording, uncontrolled artwork, and labels that refer to an obsolete device version. A study reference or lot number does not compensate for missing required risk information.
When reviewing multinational studies, assess each jurisdiction separately. A U.S. label should not be assumed to satisfy every participating country’s requirements.
Labeling and clinical-development support
BioBoston Consulting supports IDE strategy and submission needs. For defined clinical-development labeling work, BioBoston CRO provides labeling support. Align the agreed deliverables and review responsibilities with the device, study, and target jurisdictions.
Common questions about investigational device labeling
Is the investigational-device caution statement optional?
For devices subject to the applicable provision, 21 CFR 812.5(a) prescribes the caution statement. Treat it as required wording rather than an optional marketing phrase, while checking the regulation’s specific exceptions or alternatives and the relevant investigation context.
Can investigational device labeling say the device is safe and effective?
The labeling must not represent the device as safe or effective for the use under investigation, and it must not be false or misleading. Review artwork, instructions, and accompanying materials together so promotional claims do not conflict with investigational status.
Is a protocol number sufficient to meet FDA labeling requirements?
No. A protocol number may support study accountability, but it does not replace the required identification, caution, and relevant risk information. Distinguish requirements in 21 CFR 812.5 from additional traceability fields selected for the specific device and investigation.
Sources and regulatory references
References checked November 5, 2026. Regulations set binding obligations; agency guidance provides recommendations. Apply the sources within their stated scope and the requirements relevant to your product, activity, and jurisdiction.
